Non-Small-Cell Lung Cancer – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of NSCLC comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of NSCLC for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the mature markets and Europe, and 10 years for the other countries we cover.
NSCLC forecast data are available on Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s NSCLC forecast answers the following questions:
- How will changes in the levels of exposure to known risk or protective factors affect the number of people living with a diagnosis of NSCLC and the number of new diagnoses of NSCLC?
- Of all people diagnosed with NSCLC, how many in each country across the major mature pharmaceutical markets are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of NSCLC over the forecast period?
In addition to the total number of cases for each forecast year, Clarivate Epidemiology provides at least 10 years of forecast data for the following NSCLC subpopulations:
- Diagnosed incident cases
- Diagnosed adenocarcinoma NSCLC incident cases
- Diagnosed squamous cell carcinoma NSCLC incident cases
- Diagnosed large cell carcinoma NSCLC incident cases
- Diagnosed other carcinoma and NOS NSCLC incident cases
- NSCLC by stage at diagnosis
- Adenocarcinoma NSCLC by stage at diagnosis
- Squamous cell carcinoma NSCLC by stage at diagnosis
- Large cell carcinoma NSCLC by stage at diagnosis
- Other carcinoma and NOS NSCLC by stage at diagnosis
- ALK mutation status
- EGFR mutation status
- KRAS mutation status
- Metastatic recurrent incident cases
- NSCLC prevalent cases
- NSCLC drug treatable populations
- NSCLC drug treated populations
Note: Coverage may vary by country
